Exenatide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
SMC (Scotland) and TLV (Sweden) recommended or restricted exenatide, while AWMSG (Wales) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “Treatment of type 2 diabetes mellitus.”, while PBAC (Australia) recorded not recommended for “Type 2 diabetes mellitus (T2DM)”.
HAS (France) has been harder on exenatide than on its own caseload: it refused 3 of 5 decisive submissions here (60%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 14.4 years separate the first record, 28 Feb 2007 at HAS (France), from the most recent, 21 Jul 2021 at HAS (France).
TLV (Sweden) changed its position: recommended on 25 Jun 2007, restricted by 28 Feb 2012.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for exenatide, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
Nothing has been added since 2021; on this evidence the file is dormant.
6 distinct indication wordings are recorded for exenatide by the agencies that label one in English (AWMSG, PBAC and SMC).
4 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess exenatide, on 28 Feb 2007; PHARMAC (New Zealand) did not open a file until 19 Mar 2019 — an unusually long tail of 12.1 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 10 years in total.
5 of the 7 agencies here assessed exenatide more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for exenatide.
The full ledger for exenatide reads 5 not recommended, 5 recommended, 4 other and 3 restricted, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Jul 2021 | Re-assessment of SMR and ASMR | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 19 Mar 2019 | Type 2 diabetes, with established cardiovascular disease | PTAC advice: No Formal Recommendation · decision reached | source |
| PBAC (Australia) | 2016 | Type 2 diabetes mellitus (dual and triple therapy) | The PBAC recommended exenatide - Injection 2 mg per dose pre-filled pen as an Authority Re… | source |
| AWMSG (Wales) | 9 Apr 2015 | Treatment of type 2 diabetes mellitus in combination with metformin, sulphonylurea, thiazolidinedione, metformin and sul… | outside AWMSG criteria | source |
| SMC (Scotland) | 11 Jun 2012 | Adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults who have not achieved adequate glycaemic control with these agents. | withdrawn | source |
17 further decisions for exenatide, across 6 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- dapagliflozin — divergent outcome (not recommended vs recommended) on a shared indication
- saxagliptin — divergent outcome (not recommended vs recommended) on a shared indication
- vildagliptin — divergent outcome (not recommended vs recommended) on a shared indication
- empagliflozin — divergent outcome (not recommended vs recommended) on a shared indication
- pioglitazone — divergent outcome (not recommended vs recommended) on a shared indication
- dulaglutide — divergent outcome (not recommended vs recommended) on a shared indication
Coverage: 22 decisions for exenatide from 7 agencies, 2007 to 2021. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.